Roche’s changing plans show how MFN is complicating European drug launches

Live updates

1. 2h ago

   Most Favored Nation Drug Policy Forces Shifting European Launches

   United States Most Favored Nation drug pricing policies are forcing major pharmaceutical companies like Roche and Novartis to alter their European launch strategies. Roche delayed filing for European approval of its breast cancer pill giredestrant. Novartis CEO Vasant Narasimhan warned that bypassing European health systems entirely is not off the table due to access delays expected beginning in 2027. Drugmakers are reassessing global launch sequences because U.S. policy links domestic prices to lower prices abroad, complicating traditional market entry pathways.

   Why it matters

   American drug pricing overhauls are creating widespread ripple effects across the European and Swiss pharmaceutical sectors. Because pricing frameworks tie domestic costs directly to international reference prices, pharmaceutical firms face financial penalties if they introduce treatments in lower-priced European markets first. This dynamic has driven European Union ministers and pharmaceutical lobbyists to hold meetings in Dublin to counter the pricing pressure.

   What is confirmed

   • Roche will file for European approval of its breast cancer pill giredestrant later than previously planned.
   • Novartis CEO Vasant Narasimhan stated that bypassing European government health systems for new drug launches is not off the table.
   • European Union ministers and pharma lobbies met in Dublin to counter drug-pricing pushes originating from the United States.

   Still unconfirmed

   • The United States Most Favored Nation drug policy may block Europe's first Sjögren's therapy.

   What to watch next

   • Formal announcements from pharmaceutical companies regarding revised European drug launch dates and sequences.
   • Further policy responses and counter-measures from European Union health ministers regarding pricing frameworks.
   • Data on patient access delays for rare-disease treatments anticipated around 2027.
   Sources used for this update (16)

   1. mynews13.com — SpaceX successfully launches latest Starlink mission
   2. mynews13.com — SpaceX successfully launches NASA's Crew-13 mission to the ISS
   3. Endpoints News — Roche’s changing plans show how MFN is complicating European drug launches
   4. RealClearHealth — Update on Foreign Freeloading on U.S. Drug Innovation
   5. Tech Times — MFN Drug Policy Cuts US Costs; It May Block Europe's First Sjögren's Therapy
   6. La Lettre — EU ministers and pharma lobbies meet in Dublin to counter Trump's drug-pricing push
   7. SWI swissinfo.ch — Pharma pushes for higher European drug prices, Trump or no Trump
   8. www.marketscreener.com — Sanofi teases appetite for larger deals, lifts 2026 growth targets under new CEO Garijo
   9. catalystalert.io — Roche’s changing plans show how MFN is complicating European ...
   10. www.lantonlaw.com — When a Drug Launch Moves, the Business Changes Too
   11. chaindrugreview.com — MFN pricing reshapes biopharma launch strategies
   12. pharmaphorum.com — How IRA, MFN, and HTA are rewriting oncology launch strategy
   confidence 90%